

WISCONSIN DEPARTMENT OF HEALTH SERVICES



Division of Public Health Bureau of Communicable Diseases

Respiratory virus surveillance report for the week ending November 28, 2015 week 47-15

AT-A-GLANCE

- Respiratory viruses identified this week:
 Rhinovirus adenovirus and parainfluenza viruses are predominant this week.
- Influenza-like illness (ILI) activity for this week

Wisconsin Low
Wisconsin (CDC level) Minimal
Northwestern Region Moderate
Northeastern Region Low
Southeastern Region Low
Southern Region Low

- ILI activity in Region V of the U.S. (WI, MN, IL, MI, OH, IN) is below baseline levels
- ILI activity in the U.S. is below baseline levels
- The Predictive Value Positive (PVP) for rapid influenza and RSV tests is: Moderate (PVP is the probability of disease in a patient with a positive test result)
- The Predictive Value Negative (PVN) for rapid influenza and RSV tests is: High (PVN is the probability of not having disease when the test result is negative)
- Influenza-associated pediatric deaths reported (October 10, 2015-present)


| | Week 47-15 | Total to Date |
|------------|------------|---------------|
| Wisconsin | 0 | 0 |
| Nationwide | 1 | 2 |


WISCONSIN and REGIONAL SUMMARIES

(Trend analysis based on 3-week moving averages)

Wisconsin (ILI activity is Low)


| IN | INFLUENZA RAPID ANTIGEN TESTS | | | | | RSV RAPID ANTIGEN TESTS | | | INFLUENZA-LIKE ILLNESS | | | |
|--------|-------------------------------|----------|-------|--------------|--------|-------------------------|--------------|--------|------------------------|-----------|--|--|
| Tested | | Positive | | % Positive | Tested | Positive | % Positive | ILI % | Baseline | Threshold | | |
| 103100 | Flu A | Flu B | Total | 70 1 0311170 | Tostoa | 1 0311110 | 70 1 OSITIVO | 121 /0 | Dascinic | THICSHOIG | | |
| 527 | 6 | 1 | 7 | 1.3% | 108 | 6 | 5.6% | 2.1% | 2.2% | 3.4% | | |






Northwestern Region (ILI activity is Moderate)


| 1401 (1144) | JOICH INC | gion (ill | activity | is inductate) | | | | | | |
|-------------------------------|-----------|-----------|----------|---------------|---|----------|--------------|--------|----------|-----------|
| INFLUENZA RAPID ANTIGEN TESTS | | | | | RSV RAPID ANTIGEN TESTS INFLUENZA-LIKE ILLNES | | | | | ILLNESS |
| Tested | | Positive | | % Positive | Tested | Positive | % Positive | ILI % | Baseline | Threshold |
| 100100 | Flu A | Flu B | Total | 701 0011110 | 100104 | 1 001 | 70 1 0011110 | 121 70 | Bacomic | rinconord |
| 117 | 1 | 0 | 1 | 0.9% | 31 | 2 | 6.5% | 1.2% | 1.0% | 1.5% |






Northeastern Region (ILI activity is Low)


| IN | INFLUENZA RAPID ANTIGEN TESTS | | | RSV RAPID ANTIGEN TESTS | | | INFLUENZA-LIKE ILLNESS | | | |
|--------|-------------------------------|----------|-------|-------------------------|--------|-----------|------------------------|--------|----------|-----------|
| Tested | | Positive | | % Positive | Tested | Positive | % Positive | ILI % | Baseline | Threshold |
| 100104 | Flu A | Flu B | Total | 70 1 0011110 | 100100 | 1 0011110 | 70 1 0011110 | 121 70 | Basoniio | THIOGHOIG |
| 113 | 0 | 0 | 0 | 0% | 26 | 3 | 11.5% | 1.8% | 2.1% | 3.3% |






Southern Region (ILI activity is Low)


| IN | INFLUENZA RAPID ANTIGEN TESTS | | | | | APID ANTI | GEN TESTS | INFLUENZA-LIKE ILLNESS | | | |
|--------|-------------------------------|----------|-------|--------------|--------|-----------|--------------|------------------------|-----------|------------|--|
| Tested | | Positive | | % Positive | Tested | Positive | % Positive | ILI % | Baseline | Threshold | |
| 100100 | Flu A | Flu B | Total | 70 1 0011110 | 100100 | 1 0011110 | 70 1 0011110 | 121 70 | Dadoillio | Tilloonoid | |
| 53 | 0 | 1 | 1 | 1.9% | 6 | 1 | 16.7% | 0.5% | 2.3% | 3.5% | |






Southeastern Region (ILI activity is Low)

| IN | INFLUENZA RAPID ANTIGEN TESTS | | | | RSV RAPID ANTIGEN TESTS | | | INFLUENZA-LIKE ILLNESS | | | |
|--------|-------------------------------|-------------------|---|--------------|-------------------------|-----------|--------------|------------------------|----------|-------------|--|
| Tested | | Positive | | % Positive | Tested | Positive | % Positive | ILI % | Baseline | Threshold | |
| 100100 | Flu A | Flu A Flu B Total | | 70 1 0011110 | 100104 | 1 0011110 | 70 1 0011110 | 121 70 | Bacomic | 11110011010 | |
| 244 | 5 | 0 | 5 | 2.0% | 45 | 0 | 0% | 3.4% | 3.7% | 6.1% | |





For the 2015-16 influenza season, data from the Western Region and the Northern Region will be combined and referred to as the Northwestern Region. This change was made in response to the small number of providers who participate in our weekly surveillance in the Northern Region.

Influenza Vaccine Composition 2015-2016

The trivalent vaccines for use in the 2015-2016 influenza season) contain the following:

- A/California/7/2009 (H1N1)pdm09-like virus;
- A/Switzerland/9715293/2013 (H3N2)-like virus;
- B/Phuket/3073/2013-like virus (Yamagata lineage).


It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and


• B/Brisbane/60/2008-like virus (Victoria Lineage)

LABORATORY SURVEILLANCE FOR RESPIRATORY VIRUSES (PCR)

| Respiratory Agent | Tested | Positive | % Positive | Flu A | | | | Flu B | |
|-------------------|--------|----------|------------|----------|--------------|------|----------|----------|-----|
| | | | | НЗ | pd2009 H1 | Unk | Yamagata | Victoria | Unk |
| Influenza | 599 | 5 | 0.8% | 1 | 0 | 2 | 0 | 0 | 2 |
| Respiratory Agent | Tested | Positive | % Positive | PI-1 | PI | -2 | PI-3 | PI- | 4 |
| Parainfluenza | 293 | 13 | 4.4% | 12 | (|) | 0 | 1 | |
| Respiratory Agent | Tested | Positive | % Positive | CoV-229E | CoV- | OC43 | CoV-NL63 | CoV-H | KU1 |
| Coronavirus | 113 | 1 | 0.9% | 0 | (|) | 1 | 0 | |

| Respiratory Agent | Tested | Positive | % Positive |
|--------------------------|--------|----------|------------|
| RSV | 336 | 5 | 1.5% |
| Human Metapneumovirus | 271 | 4 | 1.5% |
| Rhino-entero | 233 | 37 | 15.9% |
| Adenovirus | 113 | 6 | 5.3% |





Cumulative number of positive influenza tests By subtype, September 1, 2015 to present

| | lı | nfluenza | Α | | Influenza B | | | | |
|-------------------------------------|-----------|----------|---------|----------|-------------|---------|-------|--|--|
| | pd2009 H1 | Н3 | Unknown | Yamagata | Victoria | Unknown | Total | | |
| Total Number positive | 1 | 19 | 12 | 2 | 1 | 5 | 38 | | |
| % of Total number positive | 3% | 50% | 32% | 6% | 3% | 13% | 100% | | |

Influenza-associated Hospitalizations, September 1, 2015 to present

| Age | Total Number | | | a Subtypes | | Not | Admitted | Required | |
|-------------|--------------------|--------------|------|------------|---|----------|----------|---------------------------|----------|
| group | Reported (2015-16) | 2009 H1N1 | H3N2 | A/Unknown | В | reported | to ICU | Mechanical Ventilation | Pregnant |
| < 1 year | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 1 to 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 5 to 17 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| 18 to 49 | 4 | 0 | 0 | 3 | 1 | 0 | 2 | 0 | 0 |
| 50 to 64 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | |
| 65 and over | 21 | 0 | 3 | 14 | 4 | 0 | 2 | 0 | |
| Total | 29 | 0 | 3 | 21 | 5 | 0 | 4 | 0 | 0 |

Influenza-associated Hospitalizations by Public Health Region, September 1, 2015 to present

| | September 1, 2013 to p | 71 COCIIT |
|--------------|------------------------|--------------|
| Region | Last 7 days | Season Total |
| Southeastern | 5 | 8 |
| Southern | 0 | 7 |
| Northeastern | 1 | 11 |
| Western | 0 | 2 |
| Northern | 0 | 1 |
| Wisconsin | 6 | 29 |

Incidence/100.000


| HICI | uchec/100, | 000 |
|--------------|------------|----------|
| Age group | Wisconsin | National |
| <1 | | |
| 1 to 4 | | |
| 0 to 4 | | |
| 5 to 17 | | |
| 18 to 49 | | |
| 50 to 64 | | |
| 65+ | | |
| total | | |
| | | |

NATIONAL INFLUENZA SURVEILLANCE

NCHS Mortality Surveillance Data:


Based on NCHS mortality surveillance data available on December 3, 2015, 5.9% of the deaths occurring during the week ending November 14, 2015 (week 45) were due to P&I. This percentage is below the epidemic threshold of 6.8% for week 45.

Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System Data through the week ending November 14, 2015, as of December 3, 2015



| | Week 47 | Data Cumulative since October 4, 2015 (week 40) 8,488 | |
|------------------------------------|------------|---|--|
| No. of specimens tested | 481 | | |
| No. of positive specimens | 13 | 404 | |
| Positive specimens by type/subtype | | | |
| Influenza A | 12 (92.3%) | 333 (82.4%) | |
| A(H1N1)pmd09 | 5 (41.7%) | 55 (16.5%) | |
| Н3 | 7 (58.3%) | 262 (78.7%) | |
| Subtyping not performed | 0 (0%) | 16 (4.8%) | |
| Influenza B | 1 (7.7%) | 71 (17.6%) | |
| Yamagata lineage | 0 (0%) | 13 (18.3%) | |
| Victoria lineage | 0 (0%) | 8 (11.3%) | |
| Lineage not performed | 1 (100%) | 50 (70.4%) | |

Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, 2015-2016 Season



INFLUENZA VIRUS CHARACTERIZATION

Influenza A Virus [61]


- A (H1N1)pdm09 [18]: All 18 (100%) influenza A (H1N1)pdm09 viruses were antigenically characterized as A/California7/2009-like, the influenza A (H1N1) component of the 2015-2016 Northern Hemisphere vaccine.
- A (H3N2) [43]: All 43 H3N2 viruses were genetically sequenced and all viruses belonged to genetic groups for which a majority of viruses antigenically characterized were similar to the cell-propagated A/Switzerland/9715293/2013, the influenza A (H3N2) reference virus representing the 2015-2016 Northern Hemisphere vaccine component.
 - A subset of 16 H3N2 viruses also were antigenically characterized; 15 of 16 (93.8%) H3N2 viruses were A/Switzerland/9715293/2013-like by HI testing or neutralization testing.


Influenza B Virus [1]

- Yamagata Lineage [1]: One B/Yamagata-lineage virus was antigenically characterized as B/Phuket/3073/2013-like, which is included as an influenza B component of the 2015-2016 Northern Hemisphere trivalent and quadrivalent influenza vaccines.
- Victoria Lineage [0]: No B/Victoria-lineage viruses were antigenically characterized.

Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2015

| | Oseltamivir | | Zanamivir | | Peramivir | |
|---------------------------|--------------------------------|-------------------------------------|--------------------------------|-------------------------------------|--------------------------------|-------------------------------------|
| | Virus Samples tested (n) | Resistant Viruses, Number (%) | Virus Samples tested (n) | Resistant Viruses, Number (%) | Virus Samples tested (n) | Resistant Viruses, Number (%) |
| Influenza A(H1N1)pmd09 | 11 | 0 (0.0) | 11 | 0 (0.0) | 11 | 0 (0.0) |
| Influenza A (H3N2) | 33 | 0 (0.0) | 33 | 0 (0.0) | 33 | 0 (0.0) |
| Influenza B | 12 | 0 (0.0) | 12 | 0 (0.0) | 12 | 0 (0.0) |






*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.


Seasonal Influenza Vaccination in Wisconsin Based on Doses Reported to the Wisconsin Immunization Registry (WIR) December 3, 2015

Data for 2015-2016 Season Reported for 8.1.15-12.2.2015


Cumulative Doses of Seasonal Influenza Administered and Reported to the WIR, 2008-2016 Influenza Seasons



Number of Doses of Seasonal Influenza Vaccine Administered and Reported to the WIR, by Month for Influenza Seasons 2010-2016




Doses of Seasonal Influenza Vaccine Administered and Reported to WIR by Age Group and Vaccine Type, 2015-2016 Influenza Season




^{*}Of trivalent influenza doses administered between 8/1/15 and 12/2/15 and received by adult clients aged 65 years and older, 69.4% of the doses were high dose influenza vaccine.

Rates of Influenza Vaccination in Wisconsin by Age Group, 2011-2016 Influenza Seasons, Based on Doses Reported to the Wisconsin Immunization Registry (WIR)




^{*} Numerator: Number of persons recorded in the WIR as having received at least one dose of seasonal influenza vaccine by age group. For 2012-2013 season, doses administered between 8/1/12 to 7/31/13, assessed 12/2/13. For 2013-2014, doses administered between 8/1/13 to 7/31/14, assessed 8/15/14. For 2014-2015, doses administered between 8/1/14 to 6/11/15, assessed 6/12/2015. For 2015-2016, doses administered between 8/1/15 to 12/2/15, assessed 12/3/15. Denominator source: 2012, 2013 and 2014 Wisconsin Interactive Statistics on Health (WISH) population estimates, by age group.

Rates of Influenza Vaccination in Wisconsin by Age Group, 2011-2016 Influenza Seasons, Based on Doses Reported to the Wisconsin Immunization Registry (WIR)



* Numerator: Number of persons recorded in the WIR as having received at least one dose of seasonal influenza vaccine by age group. For 2012-2013 season, doses administered between 8/1/12 to 7/31/13, assessed 12/2/13. For 2013-2014, doses administered between 8/1/13 to 7/31/14, assessed 8/15/14. For 2014-2015, doses administered between 8/1/14 to 6/11/15, assessed 6/12/15. For 2015-2016 season, doses administered between 8/1/15 to 12/2/15, assessed 12/3/15. Denominator source: 2012, 2013 and 2014 Wisconsin Interactive Statistics on Health (WISH) population estimates, by age group.

Rates of Influenza Vaccination in Wisconsin by Region, 2011-2016 Influenza Seasons, Based on Doses Reported to the Wisconsin Immunization Registry (WIR)



- * Numerator: Number of persons recorded in the WIR as having received at least one dose of seasonal influenza vaccine by region. For 2012-2013 season, doses administered between 8/1/12 to 7/31/13, assessed 11/27/13. For 2013-2014, doses administered between 8/1/13 to 7/31/14, assessed 8/15/14. For 2014-2015, doses administered between 8/1/14 to 6/11/15, assessed on 6/12/15. For 2015-2016, doses administered between 8/1/15 to 12/2/2015, assessed on 12/3/15. Denominator source: 2012, 2013 and 2014 Wisconsin Interactive Statistics on Health (WISH) population estimates, by region.
- These graphs include only doses of seasonal influenza vaccine administered and reported to the Wisconsin Immunization Registry (WIR).
- Data for 2015-16 season is incomplete because of the expected lag between the vaccine administration date and the date
 reported to the WIR, which may be a short as one day or as long as several months, depending on the submitter. Therefore,
 the current season's data will be adjusted as additional data is received.

- While use of the WIR is not mandatory, the WIR receives data from a variety of sources, including health care providers, health maintenance organizations, local health departments and tribal health centers/clinics, schools and pharmacies.
- For additional information regarding the immunization data, please contact Ashley Petit, epidemiologist, with the Wisconsin Immunization Program at (608) 266-7797.